This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

THIS PAGE BLANK (USPTO)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/10, C12Q 1/68 // C12N 9/00

1 (11) Intern

(11) International Publication Number:

WO 98/05765

| A1

(43) International Publication Date:

12 February 1998 (12.02.98)

(21) International Application Number:

PCT/DK97/00317

(22) International Filing Date:

23 July 1997 (23.07.97)

(30) Priority Data:

8/208422

7 August 1996 (07.08.96)

JР

(71) Applicant (for all designated States except US): NOVO
NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd
(DK).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): MIYOTA, Yoshiaki [JP/JP]; Showa Denko K.K., Central Research Laboratory, 1-1, Ohnodai 1-chome, Midori-ku, Chiba-shi, Chiba 267 (JP). FUKUYAMA, Shiro [JP/JP]; Showa Denko K.K., Central Research Laboratory, 1-1, Ohnodai 1-chome, Midori-ku, Chiba-shi, Chiba 267 (JP).
- (74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsvaerd (DK).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, FT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: DOUBLE-STRANDED DNA WITH COHESIVE END(S), AND METHOD OF SHUFFLING DNA USING THE SAME

(57) Abstract

To provide a method of mutation of DNAs, which is substantially different from the conventional methods applicable to naturally-existing DNAs, and also to provide useful genetic products to be produced by the use of thus-mutated DNAs. A DNA with a cohesive end comprising (a) a double-stranded DNA having the same sequence as that of a part of a gene, and (b) a single-stranded DNA having a base sequence that exists on said gene at the site not adjoining the part corresponding to said double-stranded DNA or a base sequence which said gene does not have, wherein the single-stranded DNA is linked to either one end of the double-stranded DNA to form a cohesive end; a method for producing it; a method of shuffling a DNA using it; a DNA and a DNA pool to be obtained by the shuffling method; a method for producing the DNA pool; and a genetic product to be obtained by expressing the genetic information existing in the DNA pool.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL Albania ES Spain LS Lesotho SI Slovenia AM Armenia FI Finland LT Lithuania SK Slovakia AT Austria FR France LU Luxembourg SN Senegal AU Australia GA Gabon LV Larvia SZ Swaziland AZ Azerbaijan GB United Kingdorn MC Monaco TD Chad BA Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Togo BB Barbados GH Ghana MG Madagascar TJ Tajikistan BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago	
AT Austria FR France LU Luxembourg SN Senegal AU Australia GA Gabon LV Larvia SZ Swaziland AZ Azerbaijan GB United Kingdom MC Monaco TD Chad BA Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Togo BB Barbados GH Ghana MG Madagascar TJ Tajikistan BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago	
AU Australia GA Gabon LV Larvia SZ Swaziland AZ Azerbaijan GB United Kingdorn MC Monaco TD Chad BA Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Togo BB Barbados GH Ghana MG Madagascar TJ Tajikistan BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago	
AZ Azerbaijan GB United Kingdom MC Monaco TD Chad BA Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Togo BB Barbados GH Ghana MG Madagascar TJ Tajikistan BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago	
AZ Azerbaijan GB United Kingdom MC Monaco TD Chad BA Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Togo BB Barbados GH Ghana MG Madagascar TJ Tajikistan BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago	
BA Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Togo BB Barbados GH Ghana MG Madagascar TJ Tajikistan BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago	
BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago	
BF Burkina Faso GR Grece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago	
BP Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago	
BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago	
BJ Benin IE Ireland MN Mongolia UA Ukraine	
BR Brazil IL Israel MR Mauritania UG Uganda	
BY Belarus IS Iceland MW Malawi US United States of Americ	:1
CA Canada IT Italy MX Mexico UZ Uzbekistan	
CF Central African Republic JP Japan NE Niger VN Viet Nam	
CG Congo KE Kenya NL Netherlands YU Yugoslavia	
CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe	
CI Côte d'Ivoire KP Democratic People's NZ New Zealand	
CM Cameroon Republic of Korea PL Poland	
CN China KR Republic of Korea PT Portugal	
CU Cuba KZ Kazakstan RO Romania	
CZ Czech Republic LC Saint Lucia RU Russian Federation	
DE Germany LI Liechtenstein SD Sudan	
DK Denmark LK Sri Lanka SE Sweden	
RE Estonia LR Liberia SG Singapore	

Title: Double-stranded DNA with cohesive end(s), and method of shuffling DNA using the same

5

INUSTRIAL FIELD

The present invention relates to a double-stranded DNA with a cohesive end or cohesive ends having a desired sequence and a method for producing it, and also a method for shuffling 10 a DNA using DNA blocks with a cohesive end or cohesive ends, the DNA as shuffled according to the method, a DNA pool to be obtained according to the shuffling method, and also a genetic product to be produced by the use of the DNA pool.

15 BACKGROUND ART

One approach to protein engineering for improving naturally-existing proteins to modified ones which are more useful to human beings is to improve proteins through site-specific mutation, which has produced some results (Japanese Patent 20 Application Laid-Open No. 5-91876). However, this requires the clarification or identification of the stereostructure of the targeted protein, and much labor is needed for the analysis of the stereostructure. In addition, even though the stereostructure could be clarified or identified, there are still many unknown matters for the relationship between the structure and the function with proteins. Therefore, it is still difficult to surely impart an intended function to the targeted protein.

In order to overcome these difficulties, a process comprising random mutation and screening and also evolutional molecular engineering that utilizes the evolution of organisms have been being highlighted and said to be extremely useful (Proc. Natl. Acad. Sci., USA, 83, 576 (1986)). However, the current methods are directed to the substitution of at most several amino acids.

In W095/22625, disclosed is a method for forming novel genes by dividing a plurality of genes at random and homologously recombining them to reconstruct novel genes. However, this is one method for forming chimera genes. The genes to be formed by this method are similar to the original genes, and the former shall have the essential base sequences of the latter.

Using such known methods, it is difficult to desire the impartation of some additional functions to organisms which they could not gain during the steps of their evolution. In order to obtain genetic products, of which the functions are greatly different from those of naturally-existing substances such as proteins, it is believed effective to prepare a pool of nucleic acids having significantly different base sequence spaces from those existing naturally, and to produce from them genetic products having the intended functions.

One method for this may be to prepare a nucleic acid pool 25 that covers all base combinations. However, even the total number of the base sequences that may code for a relatively small protein with 100 amino acids (300 bp) is an enormous

number of 4^{300} (about 10^{180}), and it is in fact impossible to prepare the nucleic acid pool that may cover all of them.

For proteins of some kinds, their sub-structures which are referred to as modules were specifically noted, and an attempt swas made to change the sequencing of the base sequence blocks corresponding to the individual modules to thereby produce mutants having different module sequences (Viva Origino, Vol. 23, No. 1 (1995) 86-87). In this attempt, however, the base sequences were re-sequenced merely individually for the individual mutants. No one has heretofore attempted the formation of a nucleic acid pool covering all re-sequenced molecules and the collection of genes capable of expressing products having intended properties from the pool.

Utilizing restriction enzymes, it is possible to prepare a nucleic acid pool including various molecules by blending several kinds of DNA blocks having the same cohesive end or blunt end followed by ligating them at random, and to select from this pool some molecules having desired properties. According to this method, however, the DNAs to be used must have predetermined restriction enzyme recognizing sites. Even though the DNAs have such restriction enzyme recognizing sites, there is an extremely small probability that the sites are positioned at the desired sites. In this method, in addition, the both ends of the blocks must be of the same type, and there is a high probability that the blocks are therefore self-ligated. A mans of forming the restriction enzyme recognizing sites through site-specific mutation may be taken in order to overcome these problems. However, the matter as to whether or not

the blocks can be ligated in accordance with the predetermined frame is likely much governed by chance. That is, the matter as to whether or not a desired protein can be produced without misreading the reading frame of the codon shall be governed by chance. Therefore, the method is extremely inefficient.

The subject matter of the present invention is to provide a method for efficiently obtaining base sequences that exist in spaces greatly different from those of naturally-existing base sequences, and also to provide genetic products to be obtained by expressing, as genes, the nucleic acid sequences that are obtained in that manner and that do not exist naturally.

The sequence space of a gene includes the full-length sequence thereof to be theoretically constituted by a combination of four bases, A, G, C and T. For example, a base sequentee that codes for a protein composed of a number "n" of amino acids shall be constructed by selecting and sequencing any desired one of the four bases for a total of 3n-times, therefore including 4³ⁿ combinations. Accordingly, a protein composed of 100 amino acids shall include different base sequences of about 10¹⁸ types as so mentioned hereinabove.

In fact, there is no limitation for the number of amino acids that constitute proteins. Therefore, the sequencing spaces for proteins shall extend unlimitedly. During the steps of evolution of organisms, only a part of such sequencing spaces have been examined, and there is a great probability that some sequences coding for proteins which may have some extrem ly excellent functions could exist in the other great sequencing spaces. The protein engineering studies which have been and

are being made in many laboratories and institutes at present are essentially directed to the creation of novel proteins having functions superior to those of naturally-existing proteins, and one essential approach made therein to this pursose is to substitute amino acids in existing sequences, as so mentioned hereinabove. However, the amino acid substitution is nothing but the essential means that organisms have carried out during the steps of their evolution or, that is, such is the imitation of organisms and is to search only around the sequences that organisms already examined. In addition, there is a probability that the sequences thus obtained will be those that were already weeded out in the past.

We, the present inventors have considered that, in order to be greatly apart from the sequencing spaces that organisms 15 already examined, if we carry out such matters that could not have been carried out by organisms, the purpose will be We know that the division of a gene into several attained. blocks followed by the change in the sequencing of the thus-divided blocks, if occurred in organisms, shall kill 20 organisms. Therefore, we have concluded that this method is suitable for our purpose. Having thus concluded, we, the present inventors have assiduously studied various matters relating to this method and, as a result, have found a method of forming a desired cohesive end or ends on a desired DNA. 25 lizing this method, we have succeeded in a method of dividing a gene into several blocks and re-sequencing them into different sequences and also in a method of producing a molecule pool including such different base sequences existing in different sequencing spaces, and thus have completed the present invention.

Accordingly, the present invention provides the following:

- 1) A DNA with a cohesive end comprising (a) a double5 stranded DNA having the same sequence as that of a part of a
 gene, and (b) a single-stranded DNA having a base sequence that
 exists on said gene at the site not adjoining the part corresponding to said double-stranded DNA or a base sequence which
 said gene does not have, wherein the single-stranded DNA is
 10 linked to either one end of the double-stranded DNA to form a
 cohesive end.
- stranded DNA having the same sequence as that of a part of a gene, (b) a first, single-stranded DNA having a base sequence that exists on said gene at the site not adjoining the part corresponding to said double-stranded DNA or a base sequence which said gene does not have, and (c) a second, single-stranded DNA having a base sequence that exists on said gene at the site adjoining the part corresponding to said double-stranded DNA, wherein the second, single-stranded DNA is linked to said double-stranded DNA at one end corresponding to said adjoining site, while the first, single-stranded DNA is linked thereto at the other end of the complementary strand opposite to said end, thereby forming cohesive ends.
- 25 3) The DNA with a cohesive end or cohesive ends according to the previous 1) or 2), wherein the single-stranded DNA has a length of 2 bases or more.

- 4) The DNA with a cohesive end or cohesive ends according to any one of the previous 1) to 3), wherein the cohesive end/ends is/are positioned at the 3'-terminal/terminals.
- 5) A method for producing a DNA with a cohesive end or cohesive ends, wherein a part of a DNA, as a template, and an oligonucleotide containing at least one ribonucleotide, 'as a primer, are subjected to DNA polymerase reaction to prepare a double-stranded DNA, then the ribonucleotide(s) is/are removed through enzymatic reaction or chemical reaction, and the nucleotide(s) remaining at the 5'-terminal(s) of the site(s) at which said ribonucleotide(s) existed are removed.
 - 6) A method for producing the DNA with a cohesive end of the previous 1), comprising the following steps a) to d):
- a) a step of linking (i) an oligonucleotide having the same base sequence as that of a part of a gene DNA to (ii) an oligonucleotide having a base sequence that exists on the gene at the site not adjoining the base sequence of (i) or a base sequence which the gene does not have, and containing at least one ribonucleotide, in such a manner that the oligonucleotide (i);
- b) a step of preparing a double-stranded DNA through DNA polymerase reaction between a DNA containing the part corresponding to the oligonucleotide (i) in said a), as a tem-25 plate, and the linked oligonucleotide as obtained in the previous step a), as a primer;

- c) a step of removing the ribonucleotide from said doublestranded DNA through enzymatic reaction or chemical reaction; and
- d) a step of removing the nucleotide remaining at the 5'5 terminal of the site at which said ribonucleotide existed.
 - 7) A method for producing the DNA with cohesive ends of the previous 2), comprising the following steps a) to d):
- a) a step of linking (i) an oligonucleotide having the same base sequence as that of a part of a gene DNA to (ii) an oligonucleotide having a base sequence that exists on the gene at the site not adjoining the base sequence of (i) or a base sequence which the gene does not have, and containing at least one ribonucleotide, in such a manner that the oligonucleotide (ii) is positioned at the 5'-terminal of the oligonucleotide 15 (i);
- b) a step of preparing a double-stranded DNA through DNA polymerase reaction between a DNA containing the part corresponding to the oligonucleotide (i) in said a), as a template, and (i) the linked oligonucleotide as obtained in the previous step a) and (ii) an oligonucleotide which is a complementary strand of an oligonucleotide existing on the gene at the site separated from said oligonucleotide-corresponding part by at least 3 bases or more toward the 3'-terminal and which contains at least one ribonucleotide, as primers;
- c) a step of removing the ribonucleotides from said double-stranded DNA through enzymatic reaction or chemical reaction; and

- d) a step of removing the nucleotides remaining at the 5'terminals of the sites at which said ribonucleotides existed.
- 8) A method for shuffling a DNA, comprising dividing a DNA into a plurality of DNA blocks each having a cohesive end 5 or cohesive ends, followed by ligating them together into a sequence that is different from the sequence of the original, non-divided DNA.
- 9) A method for shuffling a DNA, comprising applying the method of any one of the previous 5) to 7) to various sites of 10 a DNA, thereby dividing the DNA into a plurality of DNA blocks each having a cohesive end or cohesive ends, at least one block of which shall have a cohesive end that is complementary to the cohesive end of another block not having been directly adjacent to said one block on the original DNA, followed by ligating 15 them together into a sequence that is different from the sequence of the original, non-divided DNA.
 - 10) The shuffling method according to the previous 8) or 9), wherein the DNA is divided into 3 or more blocks.
- 11) The shuffling method according to any one of the 20 previous 8) to 10), wherein the blocks are ligated together using a DNA ligase.
 - 12) A DNA as shuffled according to the method of any one of the previous 8) to 11).
 [0016]
- 25 13) The DNA according to the previous 12), wherein a gene coding for an enzymatic function or a control gene for the gene is shuffled.

- 14) The DNA according to the previous 13), wherein the gene is a gene that codes for any one of proteases, lipases, cellulases, amylases, catalases, xylanases, oxidases, dehydrogenases, oxygenases and reductases.
- 15) The DNA according to the previous 13) or 14), wherein the gene is one derived from prokaryotes.
 - 16) The DNA according to the previous 15), wherein the gene is one derived from bacillus bacteria.
- 17) The DNA according to the previous 16), wherein the 10 gene is a protease API21 gene.
 - 18) A DNA pool containing plural kinds of DNAs having different structures that are obtained according to the shuffling method of any one of the previous 8 to 11).
- 19) The DNA pool according to the previous 18), which 15 contains 10 or more kinds of DNAs.
- applying the method of any one of the previous 5) to 7) to various sites of a template DNA to thereby prepare a mixture of DNA blocks each having a cohesive end or cohesive ends that satisfies the following conditions, followed by ligating these into any desired sequences:

Condition 1: Each block has a double-stranded site having the same sequence as that of a part of the template DNA.

Condition 2: At least two of the blocks that constitute 25 the block mixture further have, in addition to said double-stranded site, s single-stranded site (cohesive end) that is complementary to the cohesive end of blocks that are not directly adjacent to said blocks on the template DNA.

1.

Condition 3: The block mixture contains at least two different blocks which are the same in the double-stranded site but are different only in the single-stranded site and which satisfy the condition 2.

- 21) The method for producing a DNA pool according to the previous 20), wherein the template DNA is a gene that codes for an enzymatic function or a control gene DNA for the gene.
- 22) The method for producing a DNA pool according to the previous 21), wherein the template DNA is a gene DNA that codes 10 for any one of proteases, lipases, cellulases, amylases, catalases, xylanases, oxidases, dehydrogenases, oxygenases and reductases.
- 23) The method for producing a DNA pool according to the previous 22), wherein the template DNA is one derived from 15 prokaryotes.
 - 24) The method for producing a DNA pool according to the previous 23), wherein the template DNA is one derived from bacillus bacteria.
- 25) The method for producing a DNA pool according to the 20 previous 24), wherein the template DNA is a protease API21 gene.
 - 26) The method for producing a DNA pool according to any one of the previous 20) to 25), wherein the DNA blocks are ligated together using a DNA ligase.
- 25 27) A genetic product to be obtained by expressing the genetic information on DNA molecules that exist in the DNA pool of any one of the previous 18) to 26).

Now the present invention is described in detail hereinunder.

DNA with Cohesive End(s)

The present invention provides a DNA with any desired 5 cohesive end or ends (herein referred to as "DNA with cohesive end(s)" unless otherwise specifically indicated). The cohesive end as referred to herein indicates a single-stranded site as protruded from the end of a double-stranded DNA. 10 cohesive end may be formed when a DNA is cleaved with a restriction enzyme such as EcoRI. In this case, however, the base sequence of the thus-formed cohesive end is defined, depending on the restriction enzyme used, and its length is generally composed of several bases or so. If a naturally-15 existing DNA is cleaved with a restriction enzyme, the sequence of the resulting double-stranded part of the DNA is also limited to the region as sandwiched between the restriction enzyme recognizing sites. As opposed to this, the DNA with cohesive end(s) of the present invention may have a structure in 20 which a cohesive end or cohesive ends having a desired length and a desired sequence is/are added to the end or ends of a double-stranded DNA having a desired sequence.

As has been mentioned hereinabove, the sequence of the double-stranded part of the DNA with cohesive end(s) of the present invention is not specifically defined. For example, the sequence may be the same as that of a part of a gene. Though not also specifically defined, its length may be generally composed of 50 base pairs (bp) or more, preferably 45 bp

WO 98/05765 PCT/DK97/00317

13

or more. The sequence of the cohesive end is not also specifically defined, but in order to prevent the self-ligation thereof in various reactions, it is preferable that the sequence does not form a stem structure. The "sequence to form a stem structure" as referred to herein includes, for example, AATT, which shall have just the same sequence as that of its complementary strand (TTAA). The length of the cohesive end may be generally 2 bp or more, preferably from 15 bp to 30 bp. If the cohesive end is too long, it may form a secondary structure whereby the intermolecular annealing will be difficult. However, if it is too short, its melting temperature (Tm) is low and the annealing will be unstable.

The cohesive end may be linked to either the 3'-terminal or the 5'-terminal of the double-stranded DNA, but is prefe15 rably linked to the 3'-terminal thereof. The cohesive end may be linked to either only one terminal of the double-stranded DNA or the both terminals thereof.

Method for Producing DNA with Cohesive End(s)

The DNA with cohesive end(s) of the present invention can be produced typically according to a method comprising the following steps a) to d). The method mentioned below is directed to the production of a DNA with a cohesive end, which has a structure to be represented by a formula (2): wherein \times and c are desired sequences; a and Ξ are sequences that are complementary to \times and c, respectively; and ω is a sequence of a cohesive end, and which is based on a double-stranded DNA (template DNA) 5 having a structure to be represented by a formula (1):

(1)

wherein \times , c, a, Ξ , and A have the same meanings as above.

However, the present invention is not limited to only the production illustrated herein, but other DNAs with cohesive end(s) having other structures can also be produced in the same manner as below according to the present invention.

15 <u>Step a)</u>

(a-1) Preparation of Oligonucleotide:

First, the part that shall be selected as the double-stranded part of the intended DNA with a cohesive end is defined on a template DNA. An oligonucleotide, a, which is complementary to its terminal, %, and an oligonucleotide, c, having the same sequence as that of the other terminal, c, are prepared. % and c each may have a sequence having a base length of from 15 to 30 bp or so.

On the other hand, prepared is an oligonucleotide, b, 25 which is complementary to the sequence to be prepared by removing one base (this is referred to as X) from the 5'-terminal of the sequence of the intended cohesive end, &.

The base sequence, A, may be a part of the above-mentioned DNA or may be any other sequence that the DNA does not have.

These oligonucleotides, a, b and c, may be prepared by any methods. If their sequences are previously known, they can be synthesized, using a known DNA synthesizer.

(a-2) Preparation of Ribonucleotide-Containing Fragments:

Next, the oligonucleotides, a and b, are linked together via a ribonucleotide. This linkage can be attained by ordinary synthesizing methods. For example, it can be attained according to the process mentioned below.

First, a phosphoryl group is added to the 5'-terminal of the oligonucleotide, a, according to the reaction of the following formula (3):

15 (3)

wherein (P) is a phosphoryl group.

This reaction can be effected by the action of a polynucleotide kinase. ATP is used in an amount of from 2 to 10 times or so, by mol, relative to the oligonucleotide, a. The reaction temperature may be from 30 to 40°C or so. The reaction time may be from 10 minutes to 1 hour or so. Most suitably, the pH is from 7 to 9 or so. After the addition of the phosphoryl group thereto, the oligonucleotide is represented by a'.

[0024]

25 On the other hand, a ribonucleotide is added to the 3'terminal of the oligonucleotide, b, according to the reaction
of the following formula (4):

(4)

wherein X is any one of ATP, GTP, CTP and UTP; (rX) is a ribonucleotide.

This reaction can be effected by the action of, for sexample, a terminal deoxynucleotidyl transferase. For the nucleoside triphosphate (XTP) to be used herein, is selected a ribonucleotide that corresponds to the base X in the previous step (a-1). The nucleoside triphosphate is used in an amount of from 2 to 10 times, by mol, relative to the oligonucleotide, b. The reaction temperature may be from 30 to 40°C or so. The reaction time may be from 30 minutes to 2 hours or so. After the addition thereto, the oligonucleotide is represented by b'. The sequence of b' is complementary to the sequence, & .

The thus-obtained oligonucleotides, a' and b', are mixed,

15 whereby the 5'-terminal (phosphoryl group) of a' is bonded to

the 3'-terminal (hydroxyl group) of the ribonucleotide of b',

according to the reaction of the following formula (5):

(5).

20 This reaction can be effected by the action of an RNA ligase in the presence of ATP and divalent metal ions (Japanese Patent Application Laid-Open No. 5-292967). Divalent metal ions useful in this reaction include, for example, magnesium ions and manganese ions, but preferred are magnesium ions. As the ligase, employable is an RNA ligase. The RNA ligase is an enzyme to catalyze the ligation of the hydroxyl group at the 3'-terminal and the phosphoryl group at the 5'-terminal, and this also efficiently catalyzes the ligation of a

polydeoxyribonucleotide having a ribonucleotide only at its 3'terminal and a polydeoxyribonucleotide with a 5'-terminal phosphoryl group. Preferably used is a T4 RNA ligase. The
reaction is generally effected in a buffer, at a pH of from 7
5 to 9 and at a temperature of from 10 to 40°C, over a period of
from 30 to 180 minutes. For example, the oligonucleotide's may
be reacted in a solution comprising 50 mM Tris-HCl (pH 8.0), 20
mM MgCl₂, 0.1 mM ATP, 10 mg/liter BSA, 1 mM hexaammine cobalt
chloride (HCC) and 25 % polyethylene glycol 6000, at 25°C for
10 60 minutes or longer.

Step b)

Using the DNA containing the sequence, %, as prepared in the previous step (a-1), as a template, and using the linked oligonucleotide, b'-a', as prepared in the previous step (a-2), 15 as a primer, prepared is a double-stranded DNA through DNA polymerase reaction. In general, a double-stranded DNA containing the sequence, X, and a sequence, Ξ , on their strands is subjected to thermal or alkaline denaturation to give single-stranded DNAs, which are added to the primer of b'-a' 20 and subjected to PCR with the oligonucleotide, c, as prepared in the previous step (a-1). The primer annealing condition and the polymerase reaction condition to be employed herein may be the same as those in ordinary polymerase reaction. polymerase to be employed herein may be any and every enzyme 25 that can catalyze the DNA chain-extending reaction, which includes, for example, Taq polymerase, Klenow fragment, DNA polymerase I, etc. As a result of this reaction, obtained is a double-stranded DNA with blunt ends, which is represented by the a formula (6):

(6).

Step c)

Next, the ribonucleotide is removed from the doublestranded DNA through enzymatic reaction or chemical reaction.
One example of useful enzymes is a ribonuclease. The reaction
is generally effected at a pH of from 6 to 8 or so, at from 30
to 70°C or so, over a period of from 10 to 60 minutes or so.

As non-enzymatic chemicals usable herein, mentioned are sodium
hydroxide and the like. As a result of this reaction, obtained
is a partly-discontinuous, double-stranded DNA of the following
formula (7), in which the part corresponding to the abovementioned base, X, has been deleted.

15

(7).

Step d)

After the above step, the nucleotide existing at the 5'terminal of the above-mentioned deletion is removed. To remove
this nucleotide, for example, the double-stranded DNA, from
which the ribonucleotide has been removed in the previous step
c), is heated at from 50 to 90°C or so. The polynucleotide
that has been separated from the strand through this reaction
can be removed, using, for example, a span column or the like.
Thus is obtained the double-stranded DNA with a cohesive end of
the above-mentioned formula (2).

In the process mentioned above, obtained is a doublestranded DNA with a cohesive end only at its one 3'-terminal. In the same manner as this, also obtainable is a doublestranded DNA with cohesive ends at the both 3'-terminals.

In the above-mentioned process, a desired sequence, &, which does not adjoin the sequence, &, in the template DNA was introduced into the DNA to form the cohesive end. Apart from this, it is also possible to introduce thereinto an additional oligonucleotide that adjoin the sequence in the template DNA to form another cohesive end. For example, in the embodiment mentioned above, an oligonucleotide, c', which is different from the oligonucleotide, c, in that its 3'-terminal deoxyribonucleotide is substituted with a ribonucleotide, may be used as the primer in place of the oligonucleotide, c, to prepare a double-stranded DNA with two cohesive ends of a formula (8):

15 (8).

Method of Shuffling DNA

The present invention also provides a method of shuffling a DNA, which is characterized by using DNAs with cohesive end(s). The terminology "shuffling" as referred to herein in20 dicates the operation of dividing a DNA into plural blocks followed by re-sequencing them into a desired, different sequence.

For example, where one DNA has a sequence composed of a number, n, of blocks, as represented by a formula (9):

25
$$A - a1 - a2 - ... - a_n - B$$
 (9)

wherein the starting end A and/or the terminal end B may be omitted,

5

this may be shuffled according to the present invention to give a different DNA to be represented by a formula (10):

$$A - a1' - a2' - ... - a_X - B$$
 (10)

wherein al', a2', . . . , a_X are blocks that are independently selected from the group of a1, a2, . . , a_n ; and the total number of the blocks al', a2', . . . , a_X may not be the same as the total number of the blocks a1, a2, . . . , a_n .

The principle of the DNA shuffling of the present invention which utilizes DNAs with cohesive end(s) is graphically illustrated in Fig. 1. In Fig. 1, the DNA is shuffled at the intermediate part, p1 - p2 - p3 (the uppermost row) into p3 - p1 - p2 (the lowermost row), without changing the both ends pA and pB. This shuffling operation is useful as a method for obtaining gene sequences that have not heretofore existed naturally, without changing the sequences of the promoter and the terminator.

Concretely, the above-mentioned method of preparing DNAs with cohesive end(s) is applied first to the parts pA, p1, p2, p3 and pB constituting the template DNA, to thereby prepare DNA blocks, a1, a2 and a3, each having the structure with two cohesive ends (formula (8)), and DNA blocks, A and B, each having the structure with one cohesive end (formula (2)). The cohesive ends, aA, a1f, a2f and a3f, are formed by removing the corresponding complementary strand from the blocks, pA, p1, p2 and p3, respectively.

The cohesive ends, alr, alr, alr, alr and all, are designed according to the desired sequence to be prepared after the shuffling. In the embodiment of Fig. 1, the end, alr is designed to be a complementary strand to the end, all is designed to the algorithm of the end, all is block, all is ligated to the block all after the shuffling. The ligation is conducted, using a DNA ligase in the presence of ATP. The type of the DNA ligase to be employed herein is not specifically defined. In this embodiment, since the single-stranded part of each cohesive end is long, it is unnecessary to employ the ordinary reaction at 16°C, but a thermophilic DNA ligase is advantageously employed.

In the embodiment of Fig. 1, a_{2r}, a_{3r} and a_B are designed to be the complementary strands to a_{1f}, a_A and a_{2f}, respectively, in the same manner as above. As a result of the shuff-ling, a sequence having a structure of A - a₃ - a₁ - a₂ - B is finally obtained. This is seemingly the same as the resequenced order of p_A - p₃ - p₁ - p₂ - p_B to be obtained by dividing the original DNA into the constitutive blocks p₁, p₂, p₃, p_A and p_B, followed by re-sequencing these into a different sequence.

Any other desired sequences can be realized in the same manner as above. If the block, A or B, is made to have two cohesive ends, while the other blocks are made to have one cohesive end, it is possible to obtain still different sequences through shuffling where the latter blocks with one cohesive end are positioned at the terminals.

In the shuffling of the invention, it is also possible to introduce foreign DNA block(s) with cohesive end(s), which are

not in the original gene, into the gene DNA. For example, it is possible to shuffle two or more gene DNAs. In this case, the terminal of one gene, for example, the block A in the above-mentioned embodiment, may be processed into a DNA block with two cohesive ends, if desired.

The blocks, which are the units to be shuffled, are oligo- nucleotides polynucleotides composed or of 2 or nucleotides (hereinafter referred to as "oligonucleotides"). In general, these are preferably composed of 30 or more 10 nucleotide units, more preferably 45 or more nucleotide units. The uppermost limit of the block length is not specifically defined, provided that the block length is shorter than the length of one gene. If, however, the block length is too large, the re-sequenced DNA to be obtained by the shuffling 15 shall have many non-mutated base sequence parts. Therefore, in general, the block length is preferably within the range of from 10 to 35 % of the length of a gene.

Where the gene to be shuffled is a gene that codes for a protein, it is desirable that the gene blocks, oligonucleotides 20 have the same reading frame before and after the division.

Namely, the gene blocks to be shuffled are desirably so designed that they are translated to always give the corresponding amino acid sequences, irrespective of their relative positions in the shuffled sequence. For this, the double-stranded parts and the cohesive ends shall be selected for their codon units in accordance with the reading frame of the gene DNA to be shuffled.

Needless-to-say, it is unnecessary to conduct the division into segment blocks with genetic meanings. Namely, it is unnecessary to conduct the division of the gene DNA into the constitutive exons or segment blocks that correspond to the domains or modules of the protein which the gene DNA codes for. There is a probability that the shuffling at such sites would have been examined in the natural world in the past. In order to obtain base sequences that have not heretofore been examined in the natural world, it is desirable that the division of the gene DNA is effected inside the constitutive exons or at the sites corresponding to the inside of the domains or modules of the protein which the gene DNA codes for.

Employing such means, therefore, it is possible to obtain proteins which have different structures as a whole from those of natural proteins but which partly contain amino acid sequences that have been confirmed to be useful in the natural world. Accordingly, the probability of obtaining useful proteins by such means is enlarged, as compared with the means of synthesizing proteins totally at random.

The kind of the gene to be shuffled according to the present invention is not specifically defined. Employable herein is any and every gene that is composed of polynucleotide chains and contains a coding region necessary for expressing a protein or RNA. The nucleotide unit may contain any molecule of deoxy-ribonucleotides or ribonucleotides. For the purpose of finding out useful base sequences, preferred are genes coding for proteins, especially enzymes, or control genes for enzymatic functions. Examples of such enzymes include proteases, lipa-

ses, cellulases, amylases, catalases, xylanases, oxidases, dehydrogenases, oxygenases and reductases.

The kind of the gene to which the present invention is directed is not specifically defined but shall be such that, 5 when it is introduced into a suitable host, the host can produce the genetic product through expression of the gene, As examples, referred to are genes as cloned from living organisms, artificially synthesized genes, and even genes as cloned from living organisms and artificially mutated. For the genes derived from living organisms, employable are prokaryotes with definite enzyme producibility. As examples of such prokaryotes, mentioned are bacillus bacteria. One example of the genes derived from such bacteria is a protease API21 gene derived from Bacillus NKS-21 (FERM BP-93-1) (Japanese Patent Application Laid-Open No. 5-91876, Sequence Number 1).

DNA Pool

The present invention also provides a DNA pool to be obtained according to the above-mentioned shuffling method.

The "DNA pool" as referred to herein means a high-density mixture of two or more DNAs. The DNA pool of the present invention can contain a particular number or more, for example, 10 or more different DNA molecules having different structures. It is desirable that, when the mixture, DNA pool is directly used in biochemical operation or reaction, it is in such a form that all the plural nucleic acid components constituting it can be reacted. Howev r, the form of the mixture, DNA pool is not

specifically defin d, and the DNA pool may be either in solution or dry mixture.

To produce the DNA pool, for example, a plurality of cohesive ends for each block are prepared in the above-menstioned shuffling process. Referring to the embodiment of Fig. 1, for example, when, for the cohesive end alr of the block al, complementary strands to the other cohesive ends, all and alf, are prepared in addition to the complementary strand to alf, then DNAs of A - al - al - B and A - al - al - al can be obtained. If a complementary strand to the other cohesive end alf of all is added, it is also possible to produce other DNAs comprising a series of the same blocks, such as A - al - al - al - al.

In the same manner, for the cohesive ends of a2 and a3, if oligonucleotides that are complementary to the cohesive ends of the other blocks or complementary to the other cohesive end of themselves are added, other sequences comprising these can be produced.

In general, a DNA is divided into blocks of al, a2, a3, .

20 . . , an. Then, each block is processed to have a cohesive end or cohesive ends according to the above-mentioned process. The cohesive ends are designed to be oligonucleotides that are complementary to the cohesive ends of the other blocks or are complementary to the other cohesive end of themselves. All or a part of the thus-obtained DNA blocks are mixed and ligated to each other, thereby producing a nucleic acid pool containing different nucleic acids composed of the blocks as differently sequenced at random.

Expression of Genetic Information in Shuffled DNA or DNA Pool

The thus-shuffled, single or mixed, double-stranded DNAs The blunting may be omitted, if DNA blocks with one cohesive end are positioned at the ends of the shuffled, 5 double-stranded DNA. For example, the 5'-terminal of the sequence containing a DNA block with a predetermined promoter sequence, which is based on the direction of the promoter, is not made to have a cohesive end but is made to have a blunt end, while the 3'-terminal of the sequence containing a DNA block 10 with a predetermined terminator sequence, which is based on the direction of the terminator, is not made to have a cohesive end but is also made to have a blunt end. In that manner, it is possible to directly obtain a gene in which the blocks of the intended gene have been shuffled between the promoter and the 15 terminator, without blunting it. After this, the thus-shuffled DNA is inserted into a desired vector, preferably an expression vector such as pKK223-3, using a DNA ligase. the promoter sequence and the terminator sequence to be in the shuffled DNA are not limited to only one each, but a plurality of promoter 20 sequences and terminator sequences may be therein.

If desired, the polynucleotide blocks positioned at the both ends of the shuffled DNA may be designed to have suitable restriction enzyme recognizing sites. In this case, the DNA may be ligated to a suitable vector, using the defined restriction enzymes.

Next, the vector library thus produced in the manner mentioned above is introduced into a suitable host, in which the genetic information is expressed. Thus, the intended gene-

PCT/DK97/00317

for it can be obtained. Any and every ordinary host can be used herein. Preferred examples of the host include cells of E. coli, bacillus bacteria, yeasts, and lactic acid bacteria.

If desired, in-vitro transcription systems and translation systems are also employable herein. In those cases, the genetic information can be expressed even when the gene is not ligated to a vector.

The "genetic information" as referred to herein indicates

10 the information on a gene which is carried by a DNA and which

is translated into a protein or is transcribed into RNA in a

suitable living body by the DNA for itself or after having been

ligated to any other DNA or RNA.

The genetic information that is expected to be expressed

15 according to the method of the present invention is not specifically defined, but includes, for example, those on various genetic products, such as enzymes, antibodies, hormones receptor proteins and ribozymes, and those on various control functions of, for example, operators, promoters and attenuators.

Examples

Now, the present invention is described in detail hereinunder with reference to the following examples, which, 25 however, are not intended to restrict the scope of the present invention.

Example 1: Production of DNA Pool

A nucleic acid pool was produced in accordance with the process mentioned below, based on the wild-type alkali protease (Japanese Patent Application-Laid Open No. 5-91876) as cloned from a protease API21 (Bacillus NKS-21; FERM BP-93-1) having a sequence of Sequence Number 1.

(1) Step a): Preparation of Oligonucleotide Blocks for Primer(1-1) Synthesis of Oligonucleotide Blocks:

392 automatic DNA synthesizer, Model Using an 10 (manufactured by Perkin Elmer Co.), synthesized were oligonucleotides; oligo FW (Sequence Number 2), oligo (Sequence Number 3), oligo 1r (Sequence Number 4), oligo 1b (Sequence Number 5), oligo 1a (Sequence Number 6), oligo 2r (Sequence Number 7), oligo 2b (Sequence Number 8), oligo 2a 15 (Sequence Number 9), oligo 3r (Sequence Number 10), oligo 3b (Sequence Number 11), oligo 3a (Sequence Number 12), oligo 4r (Sequence Number 13), oligo 4b (Sequence Number 14), oligo 4a (Sequence Number 15) and oligo A (Sequence Number 16). are parts of the base sequence of API21 (Japanese Patent 20 Application Laid-Open No. 5-91876) (including complementary strands), or oligonucleotides containing a part of the base However, the sequence of oligo 4a is to follow glutamine of Sequence Number 1 and, and this contains a termination codon of the gene. These oligonucleotides were so 25 designed that they might be the best when the oligo A was overhung on the 3'-terminal of the amplified DNA in the experiment to follow hereinunder, using a Tag polymerase.

These oligonucleotides were synthesized in a DM trityl-on condition (that is, while the 5'-hydroxyl group was protected with dimethoxytrityl group), and purified through an OPC column. The reagents used herein were obtained from Perkin 5 Elmer Co.

(1-2) Addition of Ribonucleotide to Blocks:

Next, 500 pmols of oligo 1r, 1 nmol of ATP and 10 units of terminal deoxynucleotidyl transferase were added to a standard solution comprising:

10 50 mM Tris-HCl buffer (pH 8.0)

10 mM MgCl,

5 mM DTT (dithiothreitol)

25 % PEG 6000

1 mM HCC (hexaammine cobalt chloride)

15 10 μ g/ml BSA (bovine serum albumin),

to thereby make 10 μ l in total. The resulting solution was left at 37°C for 1 hour.

Oligo 2r, oligo 3r, oligo 4r, oligo 1b, oligo 2b, oligo 3b and oligo 4b were processed in the same manner as above. These 20 four polynucleotides thus formed are referred to as oligo 1r', oligo 2r', oligo 3r', oligo 4r', oligo 1b', oligo 2b', oligo 3b' and oligo 4b'.

(1-3) Phosphorylation:

500 pmols of oligo 1a, 1 nmol of ATP and 10 units of polynucleotide kinase were dissolved in the standard solution having the same composition as above to make 10 μ l in total. The resulting solution was left at 37_C for 1 hour. Oligo 2a, oligo 3a and oligo 4a were processed in the same manner as

above. These polynucleotides thus formed are referred to as oligo 1a', oligo 2a', oligo 3a' and oligo 4a'.

(1-4) Ligation of Oligonucleotide Blocks:

500 pmols of oligo 1a', 100 pmols of oligo 1b', 100 pmols 5 of oligo 2b', 100 pmols of oligo 3b', 100 pmols of oligo 4b', which had been obtained in the above, as well as 1 nmol of ATP and 50 units of T4 RNA ligase were added to the same standard solution as that mentioned above to make 10 μ l in total, and these were reacted at 25°C for 4 hours.

- The other combinations, oligo 2a' with oligo 1b', oligo 2b', oligo 3b' and oligo 4b'; oligo 3a' with oligo 1b', oligo 2b', oligo 3b' and oligo 4b'; and oligo 4a' with oligo 1b', oligo 2b', oligo 3b' and oligo 4b', were also reacted in the same manner as above. A mixture of the four polynucleotides thus formed as a result of this reaction, oligo 1a' ligated to oligo 1b', oligo 2b', oligo 3b' and oligo 4b', is referred to as oligo 1M; a mixture of the four polynucleotides, oligo 2a' ligated to oligo 1b', oligo 2b', oligo 3b' and oligo 4b', is referred to as oligo 2M; a mixture of the four polynucleotides, oligo 3a' ligated to oligo 1b', oligo 2b', oligo 3b' and oligo 4b', is referred to as oligo 3M; and a mixture of the four polynucleotides, oligo 3b' and oligo 4b', is referred to aligo 4b', is referred to oligo 4b', oligo 3b' and oligo 2b', oligo 3b' and oligo 4b', oligo 4a' ligated to oligo 4M.
 - (2) Steps b) to d): Formation of Gene Blocks
- A template, plasmid pSDT812 (Japanese Patent Application Laid-Open No. 1-141596), which had been prepared by inserting, into the ClaI cleaving site of pHSG396, the gene of the wild-type alkali protease as cloned from Bacillus NKS-21, was

subjected to PCR with primers, oligo 1M and oligo 2r'. The gene fragment as amplified through this reaction was treated with a ribonuclease, and then heated at 80_C for 5 minutes, whereby the polynucleotide(s) positioned at the 5'-terminal of 5 the ribonucleotide existing in the both strands or one strand was/were removed. As a result of this, prepared was a gene block with cohesive end(s). This gene block is referred to as block 1M.

The other four combinations, oligo 2M and oligo 3r', oligo 3M and oligo 4r', oligo 4M and oligo RV, and oligo FW and oligo 1r', were processed in the same manner as above. These blocks thus prepared are referred to as block 2M, block 3M, block B, and block F, respectively.

15 Example 2: Shuffling

Block 1M, block 2M, block 3M, block B and block F of the same amount were blended and ligated together, using Pfu DNA ligase.

After the ligation, the reaction mixture was subjected to 20 agarose gel electrophoresis, through which was collected the DNA fragment of about 1.5 kbp.

Example 3: Identification of Nucleic Acid Pool

The thus-collected DNA of about 1.5 kbp was digested with 25 restriction enzymes, EcoRI and BamHI, then mixed with a plasmid, pHY300PLK (manufactured by Yakulto Honsha Co.), which had been digested with restriction enzymes, EcoRI and BamHI and processed with an alkali phosphatase, and thus ligated

together, using a ligation kit (manufactured by Takara Shuzo Co.). Using the resulting DNA, cells of E. coli JM105 were transformed, from which were selected tetracycline-resistant transformants. From these transformants, plasmid DNAs were extracted, purified and analyzed according to ordinary methods. Thus were obtained 97 clones with a DNA of 1.5 kbp as inserted between the EcoRI and BamHI recognizing sites of pHY300PLK.

The base sequences of these DNAs thus obtained in the manner mentioned above were sequenced to analyze how block 1M, 10 block 2M, block 3M, block F and block B were ligated in what order or, that is, how these were shuffled. As in the principle, block F was positioned at the first site while block B at the fifth site, and block 1M, block 2M and block 3M were shuffled between the two. Table 1 shows different types of shuffling, and the number of clones with each type.

Table 1

Type of Shuffling	Number of Clones	Type of Shuffling	Number of Clones
111	2	223	2
112	5	231	5
113	2	232	.2
121	3	233	3
122	4	311	2 '
123	7	312	6
131	. 4	313	5
132	5	321	7
133	3	322	2
211	1	323	5
212	5	331	2
213	4	332	5
221	1	333	2
222	3		

As in the above, it has been confirmed that, if three blocks of one gene are shuffled according to the method of the present invention, a nucleic acid pool is obtained that covers all combinations of clones each containing the same or different three of these blocks.

10 Example 4: Screening of Genetic Products Obtained from Nucleic Acid Pool

The DNAs as produced in Example 3 were mixed. Using the resulting DNA mixture, cells of Bacillus subtilis UOTO999 were transformed. Tetracycline-resistant transformants were selected. 300 transformants were replicated on a skim milk-containing medium plate, on which were found clear zones around the colonies of 12 transformants. Accordingly, it is under-

stood that the enzyme which the shuffled gene codes for can be selected depending on its activity. The base sequences of these 12 clones that formed the clear zones were analyzed, from which it was found that these were sequenced in the same order 5 of blocks as in the wild-type enzyme.

Example 5: Detection of Genetic Products

From 10 clones (one clone forms halo, while 9 clones do not) as selected from the transformants that had obtained in 10 Example 3, and also from the host, Bacillus subtilis UOTO999, full-length RNAs were prepared. These were processed with a ribonuclease-free deoxyribonuclease, in order to remove the influence of the plasmids on the hybridization to be effected later on. Next, using oligo 1r as the probe, these were subj-15 ected to Northern hybridization. As a result, all lanes corresponding to the RNA of the transformants gave detectable bands, but no band was detected on the lanes corresponding to the RNA of the host.

20 Advantages of the Invention

According to the present invention, provided is a doublestranded DNA molecule with any desired cohesive end or ends.
Using this, it is possible to obtain various DNAs with various
base sequences which are substantially apart from the
15 naturally-existing base sequence spaces, and also a DNA pool of
a mixture of such DNAs, through simple processes. Therefore,
it is possible to obtain excellent genetic products, such as
proteins and enzymes, which could not be obtained in

WO 98/05765 PCT/DK97/00317

35

conventional methods and which were not examined by organisms in the past. In addition, according to the method of the present invention for producing a nucleic acid pool, it is possible to obtain a mixture of nucleic acids while optionally shuffling the constitutive blocks at random in the intermediate parts but fixing the terminal sequences to be predetermined, desired ones, and it is also possible to shuffle the constitutive blocks without changing the amino acid sequence which each block codes for. Therefore, as compared with a method of producing a completely-randomized nucleic acid pool, there is a high possibility that useful genetic products can be produced according to the method of the present invention.

WO 98/05765 PCT/DK97/00317

36

•

Sequence Listing

Sequence Number: 1

Length of Sequence: 1122

5 Type of Sequence: Nucleic Acid

Number of Strands: Double-stranded

Topology: Linear

Kind of Sequence: Genomic DNA

Source: Bacillus NKS-21 (FERM BP-93-1)

10 Characteristics of Sequence:

Code Indicating Characteristics: Sig Peptide

Existing Site: 1 . . . 93

Method of Determining Characteristics: S

Code Indicating Characteristics: Mat Peptide

15 Existing Site: 104 . . . 1112

Method of Determining Characteristic: S

Sequence:

ATG AAT CTT CAA AAA ATA GCC TCA GCG TTG AAG GTT AAG CAA TCG GCA48 Met Asn Leu Gln Lys Ile Ala Ser Ala Leu Lys Val Lys Gln Ser Ala

20 -100 -95 -90

TTG GTC AGC AGT TTA ACT ATT TTG TTT CTA ATC ATG CTA GGT ACG96

Leu Val Ser Ser Leu Thr Ile Leu Phe Leu Ile Met Leu Val Gly Thr

-85

-80

-75

ACT AGT GCA AAT GGT GCG AAG CAA GAG TAC TTA ATT GGT TTC AAC TCA 144 5 Thr Ser Ala Asn Gly Ala Lys Gln Glu Tyr Leu Ile Gly Phe Asn Ser

-70 -65 -60 -55

GAC AAG GCA AAA GGA CTT ATC CAA AAT GCA GGT GGA GAA ATT CAT CAT 192
Asp Lys Ala Lys Gly Leu Ile Gln Asn Ala Gly Gly Glu Ile His His
-50 -45 -40

30 GAA TAT ACA GAG TTT CCA GTT ATC TAT GCA GAG CTT CCA GAA GCA GCG 240

Glu Tyr Thr Glu Phe Pro Val Ile Tyr Ala Glu Leu Pro Glu Ala Ala
-35
-30
-25

GTA AGT GGA TTG AAA AAT AAT CCT CAT ATT GAT TTT ATT GAG GAA AAC 288 Val Ser Gly Leu Lys Asn Asn Pro His Ile Asp Phe Ile Glu Glu Asn

35 -20 -15 -10

GAA GAA GTT GAA ATT GCA CAG ACT GTT CCT TGG GGA ATC CCT TAT ATT 336

Glu Glu Val Glu Ile Ala Gln Thr Val Pro Trp Gly Ile Pro Tyr Ile

	TAC	TCG	GAT	GTT	GTT	CAT	CGT	CAA	GGT	TAC	TTT	GGG	AAC	GGA	GTA	AAA	384
	Tyr	Ser	Asp	Val		His	Arg	Gln	Gly	_		Gly	Asn	Gly		-	
					15					20					25		420
														TTA			
5	vai	WIR	val	30	-	Thr	GIY	Val	A14	Pro	HIS	PFO	Asp	Leu 40		116	
	AGA	GGA	GGA			ттт	ATC	тст		GAA	AAC	ACT	TAT	GTG		TAT	480
														Val			
		3	45					50					55			-1-	
10	AAT	GGT	CAC	GGT	ACT	CAC	GTA	GCT	GGT	ACT	GTA	GCT	GCC	CTA	AAC	AAT	528
	Asn	Gly	His	Gly	Thr	His	Val	Ala	Gly	Thr	Val	Ala	Ala	Leu	Aşn	Asn	
		60					65					70					
•														TAT			576
15	ser 75	Tyr	GLY	Val	Leu		Val	Ala	Pro	GIA		Glu	Leu	Tyr	Ala		
13		CTT	ርጥ ጥ	CAT	CCT	80	CC N	»cc	CCT	TCG	85 CAT	CCN	TCC	ATT	ССТ	90	624
														Ile			024
	-,-				95		,		,	100			201		105		
	GGA	ATT	GAA	TGG	GCG	ATG	AAT	AAT	GGG	ATG	GAT	ATT	GCC	AAC	ATG	AGT	672
20	Gly	Ile	Glu	Trp	Ala	Met	Asn	Asn	Gly	Met	Asp	Ile	Ala	Asn	Met	Ser	
				110					115					120			
														GCA			720
	Leu	Gly		Pro	Ser	Gly	Ser		Thr	Leu	Gln	Leu		Ala	Asp	Arg	
25	CCT	B.C.C	125	CCA	CCT	GTC	ጥጥክ	130	እ ጥጥ	GGG	ece	ССТ	135	AAC	TCA	CCA	768
2,3														Asn		_	700
		140	*	7114	017		145	Deu	110			150	01,			1	
	CAA		GGC	GGC	TCG	AAT		ATG	GGC	TAC	CCA	GCG	CGC	TAT	GCA	TCT	816
	Gln	Gln	Gly	Gly	Ser	Asn	Asn	Met	Gly	Tyr	Pro	Ala	Arg	Tyr	Ala	Ser	
30	155					160		*			165					170	
														GCG			864
	Val	Met	Ala	Val	_	Ala	Val	Asp	Gln		Gly	Asn	Arg	Ala		Phe	
	ጥሮል	NCC.	ጥስጥ	CCA	175	CNN	CTT	CNC	እ ጥ ጥ	180	ccc	CCT	CCT	GTC	185	እ ተ ገጥ	012
35														Val			712
•	001	001	- 1 -	190	Der	914	Dea	O L u	195	1100		110	01,	200			
	AAC	AGT	ACG		TTA	AAT	AAC	GGA	-	CGC	AGT	TTA	AAT	GGT	ACG	TCA	960
	Asn	Ser	Thr	Tyr	Leu	Asn	Asn	Gly	Tyr	Arg	Ser	Leu	Asn	Gly	Thr	Ser	
			205					210					215				
40														AAA			800
	Met		Ser	Pro	His	Val		Gly	Val	Ala	Ala		Val	Lys	Gln	Lys	
	C3.C	220	~~~	mm »	3.00		225	<i></i>	3 mm		220	230	እጥሮ	7 7 T	~ n	2021	050
														AAT Asn			.056
45	235	PIO	ure	Deu	TITE	240	ALG	GIII	TTE	nry	245	nr y	Mec	Vali	GIN	250	
••		ATT	CCG	CTT	GGT		AGC	ACG	TAT	TAT		AAT	GGC	ATT	GTG		104
														Leu			
					255				*	260	-		-		265	•	
	GCT	GAG	TAT	GCG	GCT	CAA										1	.122
50	Ala	Glu	Tyr		Ala												
	•			270		272											

Sequence Number: 2

Length of Sequence: 20

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

5 Topology: Linear

Kind of Sequence: Other Nucleic Acid, Synthetic DNA

Sequence:

GATTTTAGAA TTCGCAGCGG

10 Sequence Number: 3

Length of Sequence: 25

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

Topology: Linear

15 Kind of Sequence: Other Nucleic Acid, Synthetic DNA

Sequence:

CCGGATTCCT TAAAGCCCTG AATAA

Sequence Number: 4

20 Length of Sequence: 17

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

Topology: Linear

Kind of Sequence: Other Nucleic Acid, Synthetic DNA

25 Sequence:

ACAGTCTGTG CAATTTC

Sequence Number: 5

Length of Sequence: 17

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

Topology: Linear

5 Kind of Sequence: Other Nucleic Acid, Synthetic DNA

Sequence:

GAAATTGCAC AGACTGT

Sequence Number: 6

10 Length of Sequence: 20

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

Topology: Linear

Kind of Sequence: Other Nucleic Acid, Synthetic DNA

15 Sequence:

CCTTGGGGAA TCCCTTATAT

Sequence Number: 7

Length of Sequence: 17

20 Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

Topology: Linear

Kind of Sequence: Other Nucleic Acid, Synthetic DNA

Sequence:

25 CCCAATACGC CATATGA

Sequence Number: 8

Length of Sequence: 17

Type of Sequence: Nucleic Acid

5 Number of Strand: Single-stranded

Topology: Linear

Kind of Sequence: Other Nucleic Acid, Synthetic DNA

Sequence:

TCATATGGCG TATTGGG

10

Sequence Number: 9

Length of Sequence: 20

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

15 Topology: Linear

Kind of Sequence: Other Nucleic Acid, Synthetic DNA

Sequence:

GTGGCTCCTG GAGCTGAACT

20 Sequence Number: 10

Length of Sequence: 16

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

Topology: Linear

25 Kind of Sequence: Other Nucleic Acid, Synthetic DNA

Sequence:

TCTGATCCAT AGCTTG

Sequence Number: 11

Length of Sequence: 16

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

5 Topology: Linear

Kind of Sequence: Other Nucleic Acid, Synthetic DNA

Sequence:

CAAGCTATGG ATCAGA

10 Sequence Number: 12

Length of Sequence: 20

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

Topology: Linear

15 Kind of Sequence: Other Nucleic Acid, Synthetic DNA

Sequence:

CTTGAGATTA TGGCGCCTGG

Sequence Number: 13

20 Length of Sequence: 17

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

Topology: Linear

Kind of Sequence: Other Nucleic Acid, Synthetic DNA

25 Sequence:

TGAGCCGCAT ACTCAGC

Sequence Number: 14

Length of Sequence: 17

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

Topology: Linear

5 Kind of Sequence: Other Nucleic Acid, Synthetic DNA

Sequence:

GCTGAGTATG CGGCTCA

Sequence Number: 15

10 Length of Sequence: 20

Type of Sequence: Nucleic Acid

Number of Strand: Single-stranded

Topology: Linear

Kind of Sequence: Other Nucleic Acid, Synthetic DNA

15 Sequence:

TAATCCCTAA GGATGTACTG

Brief Description of the Drawing

Fig. 1 is a graphical view showing one embodiment of the method of 20 the present invention for shuffling a DNA.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule 13bis)

A. The indications made below relate to the microorganion page 24 , lines 12-15 to page lines.	ism referred to in the description es
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution	
National Institute of Bioscience and Human-Te Technology, Ministry of International Trade an	<u> </u>
Address of depositary institution (including postal code and	country)
1-3 Higashi 1-chome, Tsukuba-shi, Ibaraki-ker	n, Japan
Date of deposit	Accession Number
7 May 1985	FERM BP-93-1
C. ADDITIONAL INDICATIONS (leave blank if not applic	able) This information is continued on an additional
organism is only to be provided to an independent exper 28(4) EPC). And as far as Australia is concerned, the expert Regulation 3.25 of Australia Statutory Rules 1991 No 71 expert nominated by the Commissioner is authorized to I	orn or deemed withdrawn, a sample of the deposited micro- t nominated by the person requesting the sample (cf. Rule pert option is likewise requested, reference being had to Also, for Canada we request that only an independent have access to a sample of the microorganism deposited. RE MADE (if the indications are not for all designated States)
	` .
E. SEPARATE FURNISHING OF INDICATIONS (leave blad	nk if not applicable)
The indications listed below will be submitted to the Interna- tions e.g., "Accession Number of Deposit")	tional Bureau later (specify the general nature of the indica-
For receiving Office use only	Fc: International Bureau use only
This sheet was received with the international application	This sheet was received by the International Bureau
Authorized officer Annie-Greiffie Warrer-Madsen Head Clerk	Authorized officer

Form PCT/RO/134 (July 1992)

CLAIMS

- 1. A DNA with a cohesive end comprising (a) a double-stranded DNA having the same sequence as that of a part of a gene, and (b) a single-stranded DNA having a base sequence that sexists on said gene at the site not adjoining the part corresponding to said double-stranded DNA or a base sequence which said gene does not have, wherein the single-stranded DNA is linked to either one end of the double-stranded DNA to form a cohesive end.
- 2. A DNA with cohesive ends comprising (a) a doublestranded DNA having the same sequence as that of a part of a
 gene, (b) a first, single-stranded DNA having a base sequence
 that exists on said gene at the site not adjoining the part
 corresponding to said double-stranded DNA or a base sequence

 15 which said gene does not have, and (c) a second, singlestranded DNA having a base sequence that exists on said gene at
 the site adjoining the part corresponding to said doublestranded DNA, wherein the second, single-stranded DNA is linked
 to said double-stranded DNA at one end corresponding to said
 20 adjoining site, while the first, single-stranded DNA is linked
 thereto at the other end of the complementary strand opposite
 to said end, thereby forming cohesive ends.
- 3. The DNA with a cohesive end or cohesive ends as claimed in claim 1 or 2, wherein the single-stranded DNA has a 25 length of 2 bases or more.
 - 4. The DNA with a cohesive end or cohesive ends as claimed in any one of claims 1 to 3, wherein the cohesive end/ends is/are positioned at the 3'-terminal/terminals.

- 5. A method for producing a DNA with a cohesive end or cohesive ends, wherein a part of a DNA, as a template, and an oligonucleotide containing at least one ribonucleotide, as a primer, are subjected to DNA polymerase reaction to prepare a double-stranded DNA, then the ribonucleotide(s) is/are removed through enzymatic reaction or chemical reaction, and the nucleotide(s) remaining at the 5'-terminal(s) of the site(s) at which said ribonucleotide(s) existed are removed.
- 6. A method for producing the DNA with a cohesive end as 10 set forth in claim 1, comprising the following steps a) to d):
- a) a step of linking (i) an oligonucleotide having the same base sequence as that of a part of a gene DNA to (ii) an oligonucleotide having a base sequence that exists on the gene at the site not adjoining the base sequence of (i) or a base sequence which the gene does not have, and containing at least one ribonucleotide, in such a manner that the oligonucleotide (ii) is positioned at the 5'-terminal of the oligonucleotide (i);
- b) a step of preparing a double-stranded DNA through DNA 20 polymerase reaction between a DNA containing the part corresponding to the oligonucleotide (i) in said a), as a template, and the linked oligonucleotide as obtained in the previous step a), as a primer;
- c) a step of removing the ribonucleotide from said double-25 stranded DNA through enzymatic reaction or chemical reaction; and
 - d) a step of removing the nucleotide remaining at the 5'terminal of the site at which said ribonucleotide existed.

WO 98/05765 PCT/DK97/00317

- 7. A method for producing the DNA with cohesive ends as set forth in claim 2, comprising the following steps a) to d):
- a) a step of linking (i) an oligonucleotide having the same base sequence as that of a part of a gene DNA to (ii) an oligonucleotide having a base sequence that exists on the gene at the site not adjoining the base sequence of (i) or a base sequence which the gene does not have, and containing at least one ribonucleotide, in such a manner that the oligonucleotide (ii) is positioned at the 5'-terminal of the oligonucleotide 10 (i);
- b) a step of preparing a double-stranded DNA through DNA polymerase reaction between a DNA containing the part corresponding to the oligonucleotide (i) in said a), as a template, and (i) the linked oligonucleotide as obtained in the previous step a) and (ii) an oligonucleotide which is a complementary strand of an oligonucleotide existing on the gene at the site separated from said oligonucleotide-corresponding part by at least 3 bases or more toward the 3'-terminal and which contains at least one ribonucleotide, as primers;
- c) a step of removing the ribonucleotides from said double-stranded DNA through enzymatic reaction or chemical reaction; and
 - d) a step of removing the nucleotides remaining at the 5'terminals of the sites at which said ribonucleotides existed.
- 25 8. A method for shuffling a DNA, comprising dividing a DNA into a plurality of DNA blocks each having a cohesive end or cohesive ends, followed by ligating them together into a

sequence that is differ nt from the sequence of the original, non-divided DNA.

- 9. A method for shuffling a DNA, comprising applying the method as set forth in any one of claims 5 to 7 to various 5 sites of a DNA, thereby dividing the DNA into a plurality of DNA blocks each having a cohesive end or cohesive ends, at least one block of which shall have a cohesive end that is complementary to the cohesive end of another block not having been directly adjacent to said one block on the original DNA, 10 followed by ligating them together into a sequence that is different from the sequence of the original, non-divided DNA.
 - 10. The shuffling method as claimed in claim 8 or 9, wherein the DNA is divided into 3 or more blocks.
- 11. The shuffling method as claimed in any one of claims 15 8 to 10, wherein the blocks are ligated together using a DNA ligase.
 - 12. A DNA as shuffled according to the method as set forth in any one of claims 8 to 11.
- 13. The DNA as claimed in claim 12, wherein a gene coding 20 for an enzymatic function or a control gene for the gene is shuffled.
- 14. The DNA as claimed in claim 13, wherein the gene is a gene that codes for any one of proteases, lipases, cellulases, amylases, catalases, xylanases, oxidases, dehydrogenases, 25 oxygenases and reductases.
 - 15. The DNA as claimed in claim 13 or 14, wherein the gene is one derived from prokaryotes.

- 16. The DNA as claimed in claim 15, wherein the gene is one derived from bacillus bacteria.
- 17. The DNA as claimed in claim 16, wherein the gene is a protease API21 gene.
- 18. A DNA pool containing plural kinds of DNAs having different structures that are obtained according to the shuffling method as set forth in any one of claims 8 to 11.
 - 19. The DNA pool as claimed in claim 18, which contains 10 or more kinds of DNAs.
- 20. A method for producing a DNA pool, comprising applying the method as set forth in any one of claims 5 to 7 to various sites of a template DNA to thereby prepare a mixture of DNA blocks each having a cohesive end or cohesive ends that satisfies the following conditions, followed by ligating these into any desired sequences:

Condition 1: Each block has a double-stranded site having the same sequence as that of a part of the template DNA.

Condition 2: At least two of the blocks that constitute the block mixture further have, in addition to said double20 stranded site, a single-stranded site (cohesive end) that is complementary to the cohesive end of blocks that are not directly adjacent to said blocks on the template DNA.

Condition 3: The block mixture contains at least two different blocks which are the same in the double-stranded site 25 but are different only in the single-stranded site and which satisfy the condition 2.

- 21. The method for producing a DNA pool as claimed in claim 20, wherein the template DNA is a gene that codes for an enzymatic function or a control gene DNA for the gene.
- 22. The method for producing a DNA pool as claimed in 5 claim 21, wherein the template DNA is a gene DNA that codes for any one of proteases, lipases, cellulases, amylases, catalases, xylanases, oxidases, dehydrogenases, oxygenases and reductases.
- 23. The method for producing a DNA pool as claimed in claim 22, wherein the template DNA is one derived from 10 prokaryotes.
 - 24. The method for producing a DNA pool as claimed in claim 23, wherein the template DNA is one derived from bacillus bacteria.
- 25. The method for producing a DNA pool as claimed in claim 24, wherein the template DNA is a protease API21 gene.
 - 26. The method for producing a DNA pool as claimed in any one of claims 20 to 25, wherein the DNA blocks are ligated together using a DNA ligase.
- 27. A genetic product to be obtained by expressing the 20 genetic information on DNA molecules that exist in the DNA pool as set forth in any one of claims 18 to 26.




Fig. 1

INTERNATIONAL SEARCH REPORT

International application No. PCT/DK 97/00317

	*		PC1/DK 9//	00317			
A. CLAS	SIFICATION OF SUBJECT MATTER						
IPC6:	C12N 15/10, C12Q 1/68 // C12N 9/0 to International Patent Classification (IPC) or to both t	0 national classification and	IPC				
	OS SEARCHED						
Minimum d	locumentation searched (classification system followed b	oy classification symbols)	ž.				
IPC6:	C12N, C12Q						
Documenta	tion searched other than minimum documentation to the	e extent that such docum	nents are included i	in the fields searched			
	FI,NO classes as above						
Electronic d	ata base consulted during the international search (nam	e of data base and, where	practicable, searc	h terms usedy			
WPI, MI	EDLINE, DBA, BIOSIS, SCISEARCH						
C. DOCU	MENTS CONSIDERED TO BE RELEVANT						
Category*	Citation of document, with indication, where ap	propriate, of the releva	ant passages	Relevant to claim No.			
Х	Chemistry Letters, Volume 2, 19	95,		1-27			
	Koichi Nishigaki et al, "Restriction-Enzyme-Nondependent Recombination and Rearrangement of DNA (RRR)" page 131						
							
X	WO 9107506 A1 (UNITED STATES OF 1991 (30.05.91), fig. 7 and		1-4				
		·					
х	WO 9517413 A1 (EVOTEC BIOSYSTEMS 29 June 1995 (29.06.95), the especially page 8, line 3-7, page 16, line 7-11 and claim	whole document page 9, line		8-19,27			
χ Furthe	er documents are listed in the continuation of Box	C. X See pat	ent family annex	•			
	categories of cited documents: nt defining the general state of the art which is not considered	date and not in co		rnational filing date or priority lation but cited to understand			
"E" ertier do	particular relevance cument but published on or after the international filing date at which may throw doubts on priority claim(s) or which is	"X" document of particonsidered novel	cular relevance: the	claimed invention cannot be red to involve an inventive			
special :	establish the publication date of another citation or other reason (as specified) nt referring to an oral disclosure, use, exhibition or other	"Y" document of particonsidered to inve	icular relevance: the o	claimed invention cannot be when the document is a documents, such combination			
"P" docume	nt published prior to the international filing date but later than rity date claimed	being obvious to	a person skilled in the r of the same patent	e art			
	actual completion of the international search	Date of mailing of th					
41 11	-L 1007		0	1 -12- 1997			
	mber 1997 mailing address of the ISA/	Authorized officer	······································				
Sw dish f	Pat nt Office						
-	S-102 42 STOCKHOLM No. +46 8 666 02 86	Patrick Ader	s son 16 8 782 25 00				
· acenium (TO 0 000 04 00	TOO TOOLE INC. TO	, , , , , , , , , , , , , , , , , ,				

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 97/00317

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.							
Category*	WO 9522625 A1 (AFFYMAX TECHNOLOGIES N.V.), 24 August 1995 (24.08.95), the whole document, see especially page 44, line 34 - page 45, line 15	8-19,27					
	especially page 44, line 34 - page 45, line 15						
	•	,					
:							

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

. INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00317

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inte	rnational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inter	mational Searching Authority found multiple inventions in this international application, as follows:
se	e next sheet
	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00317

According to PCT rule 13.2, an international application shall relate to one invention only or a group of inventions linked by one or more of the same or corresponding "special technical features", i.e. features that define a contribution which each of the inventions makes over the prior art.

Such a unifying link would be a DNA sequence with a cohesive end comprising a double stranded DNA sequence from a gene linked to at least one single stranded DNA not adjoining the double stranded DNA sequence in the gene. However such a DNA sequences are known in the art see e.g. WO9107506 or Nishigaki et.al in the search report. No other unifying special technical feature have been found.

The application is considered to comprise of the following inventions:

Invention 1, claims 1-4: DNA sequence with a cohesive end comprising a double stranded DNA sequence from a gene linked to at least one single stranded DNA not adjoining the double stranded DNA sequence in the gene.

Invention 2, claims 5-7 and 20-26, and related parts of claim 27: A method for producing DNA sequence with cohesive ends using ribonucleotides as a primer to create a double stranded DNA with polymerase reaction, whereafter the ribonucletides are removed to create a cohesive end and a method for producing a DNA pool by applying the method.

Invention 3, claim 8-19 and related parts of claim 27: A method for shuffling a DNA and a DNA pool containing DNAs obtained by the method.

In spite of the non-unity all claims have been searched.

INTERNATIONAL SEARCH REPORT

International application No. 01/10/97 | PCT/DK 97/00317

	stent document i in search repo	rt	Publication date		Patent family member(s)		Publication date
WO	9107506	A1	30/05/91	AU	6886991	A	13/06/91
WO	9517413	A1	29/06/95	DE	4343591	A	22/06/95
WO	9522625	A1	24/08/95	AU CA CN EP US	2971495 2182393 1145641 0752008 5605793	A A A	04/09/95 24/08/95 19/03/97 08/01/97 25/02/97

THIS PAGE BLANK (USPTO)